Cargando…

What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?

INTRODUCTION: Though clinical benign prostatic hyperplasia (BPH) is a common disease worldwide, there is still much confusion in the literature and the many clinical guidelines as to its definition. Often the disease is associated with lower urinary tract symptoms (LUTS) and managed according to onl...

Descripción completa

Detalles Bibliográficos
Autor principal: Foo, Keong Tatt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620380/
https://www.ncbi.nlm.nih.gov/pubmed/30805683
http://dx.doi.org/10.1007/s00345-019-02691-0
_version_ 1783434037935734784
author Foo, Keong Tatt
author_facet Foo, Keong Tatt
author_sort Foo, Keong Tatt
collection PubMed
description INTRODUCTION: Though clinical benign prostatic hyperplasia (BPH) is a common disease worldwide, there is still much confusion in the literature and the many clinical guidelines as to its definition. Often the disease is associated with lower urinary tract symptoms (LUTS) and managed according to only symptoms. This leads to undertreatment in some patients with severe bladder outlet obstruction (BOO) with no symptoms, and overtreatment in patients with LUTS but no clinical BPH. DEFINITION OF A DISEASE: Fundamentally, a disease can be defined as an abnormal structure or function or a condition which may cause harm to the organism. DEFINITION OF CLINICAL BPH: Thus, clinical BPH can be defined as prostate adenoma/adenomata, causing a varying degree of BOO, which may eventually cause harm to the patients. With this definition, we are then able to differentiate the disease clinical BPH from the many other less common causes of LUTS, and then treat it according to its severity. DIAGNOSING CLINICAL BPH: Clinical BPH can be diagnosed with non-invasive ultrasound in the clinic, grading it according to the shape (intravesical prostatic protrusion) and size of the prostate. CLINICAL SIGNIFICANCE: Treatment can then be planned according to the disease severity using our staging system that classifies severity according to the presence or absence of significant obstruction and bothersomeness of symptoms. CONCLUSION: This would lead to better individualised and cost-effective management of the disease clinical BPH.
format Online
Article
Text
id pubmed-6620380
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-66203802019-07-28 What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? Foo, Keong Tatt World J Urol Invited Review INTRODUCTION: Though clinical benign prostatic hyperplasia (BPH) is a common disease worldwide, there is still much confusion in the literature and the many clinical guidelines as to its definition. Often the disease is associated with lower urinary tract symptoms (LUTS) and managed according to only symptoms. This leads to undertreatment in some patients with severe bladder outlet obstruction (BOO) with no symptoms, and overtreatment in patients with LUTS but no clinical BPH. DEFINITION OF A DISEASE: Fundamentally, a disease can be defined as an abnormal structure or function or a condition which may cause harm to the organism. DEFINITION OF CLINICAL BPH: Thus, clinical BPH can be defined as prostate adenoma/adenomata, causing a varying degree of BOO, which may eventually cause harm to the patients. With this definition, we are then able to differentiate the disease clinical BPH from the many other less common causes of LUTS, and then treat it according to its severity. DIAGNOSING CLINICAL BPH: Clinical BPH can be diagnosed with non-invasive ultrasound in the clinic, grading it according to the shape (intravesical prostatic protrusion) and size of the prostate. CLINICAL SIGNIFICANCE: Treatment can then be planned according to the disease severity using our staging system that classifies severity according to the presence or absence of significant obstruction and bothersomeness of symptoms. CONCLUSION: This would lead to better individualised and cost-effective management of the disease clinical BPH. Springer Berlin Heidelberg 2019-02-25 2019 /pmc/articles/PMC6620380/ /pubmed/30805683 http://dx.doi.org/10.1007/s00345-019-02691-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Invited Review
Foo, Keong Tatt
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title_full What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title_fullStr What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title_full_unstemmed What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title_short What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
title_sort what is a disease? what is the disease clinical benign prostatic hyperplasia (bph)?
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620380/
https://www.ncbi.nlm.nih.gov/pubmed/30805683
http://dx.doi.org/10.1007/s00345-019-02691-0
work_keys_str_mv AT fookeongtatt whatisadiseasewhatisthediseaseclinicalbenignprostatichyperplasiabph